Linezolid

Pre-clinicalWithdrawn

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Ventilator Acquired Pneumonia

Conditions

Ventilator Acquired Pneumonia

Trial Timeline

Jul 1, 2010 → Mar 1, 2011

NCT ID

NCT01040585

About Linezolid

Linezolid is a pre-clinical stage product being developed by Pfizer for Ventilator Acquired Pneumonia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01040585. Target conditions include Ventilator Acquired Pneumonia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01805284	Approved	Completed	Feb 1, 2013	Sep 30, 2016	Pneumonia
NCT01040585	Pre-clinical	Withdrawn	Jul 1, 2010	Mar 1, 2011	Ventilator Acquired Pneumonia
NCT00255996	Phase 1	Completed	May 1, 2006	Jan 1, 2007	Burns
NCT01564758	Pre-clinical	Completed	Feb 1, 2004	Mar 1, 2005	Gram-Positive Bacterial Infections
NCT00147511	Approved	Completed	Jun 1, 2003	Jun 1, 2005	Gram-Positive Bacterial Infections
NCT00150332	Phase 3	Completed	Jan 1, 2003	Jan 1, 2006	Infections, Nosocomial

Competing Products

9 competing products in Ventilator Acquired Pneumonia

See all competitors

Product	Company	Stage	Hype Score
Doripenem + Imipenem-Cilastatin + Placebo	Johnson & Johnson	Phase 3	77
Imipenem/cilastatin + Imipenem/cilastatin + Doripenem + Doripenem	Johnson & Johnson	Phase 2	52
Ceftolozane/Tazobactam + Piperacillin/Tazobactam	Merck	Phase 3	77
Imipenem + Imipenem	Merck	Approved	85
Vancomycin + Linezolid	Pfizer	Approved	84
anidulafungin	Pfizer	Phase 2	51
aerosolized vancomycin or gentamicin	Nektar Therapeutics	Phase 2	47
IC43 + Placebo	Valneva SE	Phase 2	47
Ceftobiprole	Basilea Pharmaceutica	Phase 1	28

Other Products from Pfizer